Johnson & Johnson (JNJ) shares have recently traded above the average analyst 12-month target price of $180.54, reaching $181.62/share. This development typically prompts analysts to either downgrade on valuation or raise their price targets, especially as analyst sentiment has shown improvement, with 'Strong Buy' ratings increasing and the average rating moving from 2.17 to 2.04 over the past three months. Investors are now prompted to reassess JNJ's valuation to determine if the stock has further upside or if it is approaching a point of overextension.
Johnson & Johnson (JNJ) shares have recently surpassed the average 12-month analyst price target of $180.54, reaching a trading price of $181.62. This event is occurring alongside a notable positive shift in analyst sentiment. Over the past three months, the number of 'Strong Buy' ratings has increased from 9 to 11, while 'Hold' ratings have declined, causing the average analyst rating to improve from 2.17 to 2.04 on a 1-to-5 scale where 1 is 'Strong Buy'. While the stock has exceeded the average target, the wide dispersion of individual targets, ranging from $155.00 to a high of $206.00 with a standard deviation of $12.82, indicates a lack of consensus. The improving sentiment suggests that analysts may be poised to raise their targets, viewing the price appreciation as fundamentally justified, rather than an indication of overvaluation. The key signal is not the breach of a static average, but the dynamic trend of increasingly bullish analyst conviction.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
